dc.creatorBetting L.E.
dc.creatorGuerreiro C.A.M.
dc.date2008
dc.date2015-06-30T19:15:30Z
dc.date2015-11-26T14:40:21Z
dc.date2015-06-30T19:15:30Z
dc.date2015-11-26T14:40:21Z
dc.date.accessioned2018-03-28T21:46:35Z
dc.date.available2018-03-28T21:46:35Z
dc.identifier
dc.identifierJournal Of Epilepsy And Clinical Neurophysiology. , v. 14, n. SUPPL. 2, p. 25 - 31, 2008.
dc.identifier16762649
dc.identifier
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-70549102242&partnerID=40&md5=6f31e46a2428416d32530b4a036cff90
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/105455
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/105455
dc.identifier2-s2.0-70549102242
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1250376
dc.descriptionPartial epilepsies are the most common form of epilepsy in adult individuals. Antiepileptic drugs (AEDs) continue as the main form of treatment for patients with epilepsy. Regardless of the importance of the medication a high number of patients are under inappropriate or not receiving AEDs. There are several medications available for the treatment of epilepsy. The choice of a particular medication or association among AEDs may be individualized as much as possible. In this article some aspects such as classification, onset of the seizures, age, sex, associated medical conditions, cost and posology of AEDs and medical drug history are reviewed. Details of the available AEDs are also discussed. These points may help to create a profile helping the decision for the appropriate AED. Some practical issues like adverse reaction management, monotherapy and politherapy are also discussed.
dc.description14
dc.descriptionSUPPL. 2
dc.description25
dc.description31
dc.descriptionGuerreiro, C.A.M., Palmini, A., Tratamento medicamentoso das epilepsias (2002) Epilepsia, pp. 319-337. , Guerreiro CAM, Guerreiro MM, Cendes F, Lopes-Cendes I, eds. São Paulo: Lemos Editorial
dc.descriptionLi, L.M., Fernandes, P.T., Noronha, A.L., Demonstration Project on Epilepsy in Brazil: Situation assessment (2007) Arq Neuropsiquiatr, 65 (SUPPL. 1), pp. 5-13
dc.descriptionProposal for revised classification of epilepsies and epileptic syndromes (1989) Epilepsia, 30, pp. 389-399. , Commission on Classification and Terminology of the International League Against Epilepsy
dc.descriptionThomas, P., Valton, L., Genton, P., Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy (2006) Brain, 129, pp. 1281-1292
dc.descriptionSemah, F., Picot, M.-C., Adam, C., Broglin, D., Arzimanoglou, A., Bazin, B., Cavalcanti, D., Baulac, M., Is the underlying cause of epilepsy a major prognostic factor for recurrence? (1998) Neurology, 51 (5), pp. 1256-1262
dc.descriptionBetting, L.E., Cendes, F., Crise única (2008) Tratamento Das Doenças Neurológicas, pp. 502-506. , Melo-Souza SE, ed. Rio de Janeiro: Guanabara-Koogan
dc.descriptionHauser, W.A., Rich, S.S., Lee, J.R.J., Annegers, J.F., Anderson, V.E., Risk of recurrence after two unprovoked seizures (1998) N Engl J Med, 338, pp. 429-434
dc.descriptionKwan, P., Brodie, M.J., Early identification of refractory epilepsy (2000) N Engl J Med, 342, pp. 314-319
dc.descriptionBetting, L.E., Kobayashi, E., Montenegro, M.A., Min, L.L., Cendes, F., Guerreiro, M.M., Guerreiro, C.A.M., Treatment of epilepsy: Consensus of the Brazilian specialists (2003) Arquivos de Neuro-Psiquiatria, 61 (4), pp. 1045-1070
dc.descriptionFrench, J.A., Kanner, A.M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C.L., Theodore, W.H., Glauser, T.A., Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society (2004) Neurology, 62 (8), pp. 1252-1260
dc.descriptionZaccara, G., Franciotta, D., Perucca, E., Idiosyncratic adverse reactions to antiepileptic drugs (2007) Epilepsia, 48 (7), pp. 1223-1244. , DOI 10.1111/j.1528-1167.2007.01041.x
dc.descriptionBerg, A.T., Shinnar, S., Relapse following discontinuation of antiepileptic drugs: A meta-analysis (1994) Neurology, 44 (4), pp. 601-608
dc.descriptionBeghi, E., Di Mascio, R., Tognoni, G., Drug treatment of epilepsy. Outlines, criticism and perspectives (1986) Drugs, 31 (3), pp. 249-265
dc.descriptionMattson, R.H., Cramer, J.A., Collins, J.F., Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures (1985) N Engl J Med, 313, pp. 145-151
dc.descriptionRowan, A.J., Reflections on the treatment of seizures in the elderly population (1998) Neurology, 51, pp. S28-33
dc.descriptionEnsrud, K.E., Walczak, T.S., Blackwell, T., Ensrud, E.R., Bowman, P.J., Stone, K.L., Antiepileptic drug use increases rates of bone loss in older women: A prospective study (2004) Neurology, 62 (11), pp. 2051-2057
dc.descriptionValimaki, M.J., Tiihonen, M., Laitinen, K., Tahtela, R., Karkkainen, M., Lamberg-Allardt, C., Makela, P., Tunninen, R., Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs (1994) Journal of Bone and Mineral Research, 9 (5), pp. 631-637
dc.descriptionFarhat, G., Yamout, B., Mikati, M.A., Demirjian, S., Sawaya, R., El-Hajj Fuleihan, G., Effect of antiepileptic drugs on bone density in ambulatory patients (2002) Neurology, 58 (9), pp. 1348-1353
dc.descriptionSato, Y., Kondo, I., Ishida, S., Motooka, H., Takayama, K., Tomita, Y., Maeda, H., Satoh, K., Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy (2001) Neurology, 57 (3), pp. 445-449
dc.descriptionJohannessen Landmark, C., Antiepileptic drugs in non-epilepsy disorders: Relations between mechanisms of action and clinical efficacy (2008) CNS Drugs, 22 (1), pp. 27-47
dc.descriptionVanotti, A., Osio, M., Mailland, E., Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies (2007) CNS Drugs, 21 (SUPPL. 1), pp. 3-12
dc.descriptionPerucca, E., Dulac, O., Shorvon, S., Tomson, T., Harnessing the clinical potential of antiepileptic drug therapy: Dosage optimisation (2001) CNS Drugs, 15 (8), pp. 609-621
dc.descriptionRuble, J., Matsuo, H., Anticonvulsant-induced cutaneous reactions. Incidence, mechanisms and management (1999) CNS Drugs, 12, pp. 215-236
dc.descriptionGlauser, T., Ben-Menachem, E., Bourgeois, B., Cnaan, A., Chadwick, D., Guerreiro, C., Kalviainen, R., Tomson, T., ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes (2006) Epilepsia, 47 (7), pp. 1094-1120. , DOI 10.1111/j.1528-1167.2006.00585.x
dc.descriptionDichter, M.A., Old and new mechanisms of antiepileptic drug actions (1993) Epilepsy Res, 10 (SUPPL.), pp. 9-17
dc.descriptionBrodie, M.J., Dichter, M.A., Antiepileptic drugs (1996) N Engl J Med, 334, pp. 168-175
dc.descriptionTwyman, R.E., Rogers, C.J., Macdonald, R.L., Differential regulation of γ-aminobutyric acid receptor channels by diazepam and phenobarbital (1989) Annals of Neurology, 25 (3), pp. 213-220. , DOI 10.1002/ana.410250302
dc.descriptionOxcarbazepine (1989) Lancet, 2, pp. 196-198
dc.descriptionDichter, M.A., Brodie, M.J., New antiepileptic drugs (1996) N Engl J Med, 334, pp. 1583-1590
dc.descriptionMarson, A.G., Al-Kharusi, A.M., Alwaidh, M., Appleton, R., Baker, G.A., Chadwick, D.W., Cramp, C., Williamson, P.R., The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: An unblinded randomised controlled trial (2007) Lancet, 369 (9566), pp. 1000-1015. , DOI 10.1016/S0140-6736(07)60460-7, PII S0140673607604607
dc.descriptionPanayatopoulos, C.P., Evidence-based Epileptology, Randomized Controlled Trials, and SANAD: A Critical Clinical View (2007) Epilepsia, 48, pp. 1268-1274
dc.descriptionCheung, H., Kamp, D., Harris, E., An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels (1992) Epilepsy Res, 13, pp. 107-112
dc.descriptionMontenegro, M.A., Ferreira, C.M., Cendes, F., Li, L.M., Guerreiro, C.A.M., Clobazam as add-on therapy for temporal lobe epilepsy and hippocampal sclerosis (2005) Canadian Journal of Neurological Sciences, 32 (1), pp. 93-96
dc.descriptionEngel Jr., J., Wiebe, S., French, J., Quality Standards Subcommittee of the American Academy of Neurology
dc.descriptionAmerican Epilepsy Society
dc.descriptionAmerican Association of Neurological Surgeons. Practice parameter: Temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology (2003) Neurology, 60, pp. 538-547
dc.descriptionGilliam, F., Kuzniecky, R., Faught, E., Black, L., Carpenter, G., Schrodt, R., Patient-validated content of epilepsy-specific quality-of-life measurement (1997) Epilepsia, 38 (2), pp. 233-236. , DOI 10.1111/j.1528-1157.1997.tb01102.x
dc.descriptionLehrner, J., Kalchmayr, R., Serles, W., Olbrich, A., Pataraia, E., Aull, S., Bacher, J., Baumgartner, C., Health-related quality of life (HRQOL), activity of daily living (ADL) and depressive mood disorder in temporal lobe epilepsy patients (1999) Seizure, 8 (2), pp. 88-92. , DOI 10.1053/seiz.1999.0272
dc.descriptionPerrine, K., Hermann, B.P., Meador, K.J., The relationship of neuropsychological functioning to quality of life in epilepsy (1995) Arch Neurol, 52, pp. 997-1003
dc.descriptionBoylan, L.S., Flint, L.A., Labovitz, D.L., Jackson, S.C., Starner, K., Devinsky, O., Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy (2004) Neurology, 62 (2), pp. 258-261
dc.languagept
dc.publisher
dc.relationJournal of Epilepsy and Clinical Neurophysiology
dc.rightsaberto
dc.sourceScopus
dc.titlePartial Epilepsies Treatment [tratamento Das Epilepsias Parciais]
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución